FI964473A - Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II) - Google Patents

Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II) Download PDF

Info

Publication number
FI964473A
FI964473A FI964473A FI964473A FI964473A FI 964473 A FI964473 A FI 964473A FI 964473 A FI964473 A FI 964473A FI 964473 A FI964473 A FI 964473A FI 964473 A FI964473 A FI 964473A
Authority
FI
Finland
Prior art keywords
compounds
preparation
amino acid
pharmaceutical compositions
compositions containing
Prior art date
Application number
FI964473A
Other languages
English (en)
Swedish (sv)
Other versions
FI964473A0 (fi
Inventor
Gerd Schnorrenberg
Franz Esser
Horst Dollinger
Birgit Jung
Georg Speck
Erich Buerger
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4445939A external-priority patent/DE4445939A1/de
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of FI964473A publication Critical patent/FI964473A/fi
Publication of FI964473A0 publication Critical patent/FI964473A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964473A 1994-05-07 1996-11-07 Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II) FI964473A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4416255 1994-05-07
DE4445939A DE4445939A1 (de) 1994-05-07 1994-12-22 Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen (II)
PCT/EP1995/001691 WO1995030687A1 (de) 1994-05-07 1995-05-04 Neurokinin (tachykinin)-antagonisten

Publications (2)

Publication Number Publication Date
FI964473A true FI964473A (fi) 1996-11-07
FI964473A0 FI964473A0 (fi) 1996-11-07

Family

ID=25936418

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964473A FI964473A0 (fi) 1994-05-07 1996-11-07 Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II)

Country Status (20)

Country Link
US (2) US5712273A (fi)
EP (1) EP0804463A1 (fi)
JP (1) JPH09512806A (fi)
CN (1) CN1147260A (fi)
AU (1) AU690275B2 (fi)
BG (1) BG100946A (fi)
CA (1) CA2189764A1 (fi)
CZ (1) CZ325496A3 (fi)
EE (1) EE9600186A (fi)
FI (1) FI964473A0 (fi)
HR (1) HRP950276A2 (fi)
HU (1) HUT75708A (fi)
IL (1) IL113625A0 (fi)
MX (1) MX9605128A (fi)
NO (1) NO964700D0 (fi)
NZ (1) NZ285750A (fi)
PL (1) PL317127A1 (fi)
RO (1) RO115355B1 (fi)
SK (1) SK142696A3 (fi)
WO (1) WO1995030687A1 (fi)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610487B1 (de) * 1992-09-03 1999-11-10 Boehringer Ingelheim Pharma KG Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
DE19541283A1 (de) 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19623950A1 (de) * 1996-06-15 1997-12-18 Boehringer Ingelheim Kg Pharmazeutische Zubereitung in Form von Liposomen
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6828331B1 (en) * 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1229913A4 (en) 1999-11-18 2005-01-19 Antexpharma Inc SUBSTITUTED 1-BENZAZEPINE AND THEIR DERIVATIVES
US7125840B2 (en) * 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US20060167268A1 (en) * 2002-04-09 2006-07-27 Eli Lilly And Company, Patent Division, Growth hormone secretagogues
US7396846B2 (en) * 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7238560B2 (en) * 2004-07-23 2007-07-03 Cree, Inc. Methods of fabricating nitride-based transistors with a cap layer and a recessed gate
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
KR101589551B1 (ko) 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (fi) 2011-04-21 2015-06-12 Piramal Entpr Ltd
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
CN110383066B (zh) 2016-12-09 2023-03-31 戴纳立制药公司 化合物、组合物和方法
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
GB9023116D0 (en) * 1990-10-24 1990-12-05 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
EP0610487B1 (de) * 1992-09-03 1999-11-10 Boehringer Ingelheim Pharma KG Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Also Published As

Publication number Publication date
MX9605128A (es) 1997-08-30
EP0804463A1 (de) 1997-11-05
HRP950276A2 (en) 1997-04-30
WO1995030687A1 (de) 1995-11-16
JPH09512806A (ja) 1997-12-22
NO964700L (no) 1996-11-06
EE9600186A (et) 1997-08-15
NZ285750A (en) 1998-08-26
SK142696A3 (en) 1997-06-04
BG100946A (en) 1997-07-31
AU2524995A (en) 1995-11-29
PL317127A1 (en) 1997-03-17
HU9603082D0 (en) 1997-01-28
US5712273A (en) 1998-01-27
FI964473A0 (fi) 1996-11-07
HUT75708A (en) 1997-05-28
US5700827A (en) 1997-12-23
CZ325496A3 (en) 1997-09-17
CN1147260A (zh) 1997-04-09
AU690275B2 (en) 1998-04-23
IL113625A0 (en) 1995-08-31
NO964700D0 (no) 1996-11-06
RO115355B1 (ro) 2000-01-28
CA2189764A1 (en) 1995-11-16

Similar Documents

Publication Publication Date Title
FI964473A0 (fi) Uudet aminohappojohdannaiset, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset (II)
HUP9801045A3 (en) Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation
HUP9801044A3 (en) Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them
EE9900115A (et) Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
EE200000315A (et) Heterotsüklilised ühendid maohappesekretsiooni inhibeerimiseks, protsess nende valmistamiseks ja ravimkoostised
FI942076A (fi) Sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkaaineina
IL115685A0 (en) Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
IL103126A (en) 5-amino-4-hydroxyhexanoic acid derivatives, process for their preparation and pharmaceutical compositions containing them
HUT71106A (en) Propenoic acid derivatives, pharmaceutical compositions containing them and process for their preparation
IL95503A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
HUP0002404A3 (en) Amino acid derivatives, pharmaceutical compositions comprising thereof, process for preparation them and their use
IL115072A (en) Pharmaceutical compositions containing substituted 4-phenyl-6-amino-nicotinic acid derivatives their preparation some such new compounds and process for their preparation
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
FI950625A (fi) Polysubstituoituja 3-asyyliamino-5-fenyyli-1,4-bentsodiatsepiini-2-onijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
IL112936A0 (en) Quinolone - and - naphthyridone - carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
HUP9900767A3 (en) Pyrrolidinyl hydroxamic acid derivatives and their intermediates, preparation thereof, pharmaceutical compositions containing these compounds
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
FI956278A0 (fi) Substituoituja 4-fenyylitiatsolijohdannaisia, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
HUT72319A (en) Epoxy-succinic acid derivatives, pharmaceutical compositions containing them and process for their preparation
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
EE200200331A (et) Hargnenud ahelaga asendatud 3-amino-1-fenüül-1H-[1,2,4]triasooli aminoderivaadid, nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
IL98576A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
EP0754693A3 (fr) Nouveaux dérivés d'acide aminophénylphosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
EE03803B1 (et) a-amino- ja tsüklopentaan-ß-aminohapet(-happeid) ja/või nende derivaate sisaldavad segud ja dipeptiidid, dipeptiidide valmistamismeetod ning nimetatud segusid ja/või dipeptiide sisaldavad ravimid
FI951561A0 (fi) Uudet 17 -substituoidut 4-androstaanijohdannaiset, niitä sisältävät farmaseuttiset koostumukset ja menetelmä niiden valmistamiseksi